Repair Biotechnologies

Repair Biotechnologies is pioneering a first-in-class Cholesterol Degrading Platform (CDP) designed to treat diseases caused by localized cholesterol accumulation. Its most advanced application targets the reversal of atherosclerosis, with preclinical data showing significant plaque reduction. The company is privately held, in the pre-clinical stage, and has established a key manufacturing partnership with AGC Biologics to advance its mRNA-based therapeutic candidates.

Cholesterol Degrading Platform (CDP): A therapeutic platform designed to provide human cells with the ability to safely degrade excess cholesterol, addressing the root cause of diseases like atherosclerosis and MASH. It utilizes genetic delivery (e.g., AAV, mRNA) to enable intracellular cholesterol catabolism.

Competition is fierce, primarily from large pharma companies with next-generation lipid-modifying drugs (e.g., siRNA, gene silencing) that powerfully lower LDL but still primarily slow progression. A key competitive differentiator for Repair is its direct aim to regress existing plaque, a goal pursued by only a handful of other early-stage biotechs.